Introduction

Patients with rheumatoid arthritis (RA) and type 2 diabetes (T2D) face a significantly elevated cardiometabolic risk compared to the general population. Managing these comorbidities requires therapies that offer systemic benefits beyond glycemic control. Recent evidence highlights the importance of GLP-1 RA clinical outcomes in this specific cohort, suggesting that these agents may provide superior protection compared to traditional dipeptidyl peptidase-4 inhibitors (DPP-4is).

Study Design and Methodology

A recent large-scale retrospective cohort study utilized the TriNetX US Collaborative Network to evaluate adults with both RA and T2D. The researchers employed an active-comparator, new-user design to compare patients initiating glucagon-like peptide-1 receptor agonists (GLP-1 RAs) against those starting DPP-4is between 2016 and 2023. Using 1:1 propensity score matching, the study followed over 4,600 patients in each group for up to four years to assess all-cause mortality, major adverse cardiovascular events (MACE), and kidney outcomes.

Impact on Survival and Renal Health

The study results demonstrated that GLP-1 RA use was associated with a 32% lower risk of all-cause mortality. Furthermore, patients treated with GLP-1 RAs experienced an 11% reduction in major adverse kidney events (MAKE). Interestingly, while there was no significant difference in MACE between the two groups, GLP-1 RA therapy led to 8% fewer all-cause hospitalizations. These GLP-1 RA clinical outcomes were consistent across various subgroups and sensitivity analyses, reinforcing the reliability of the findings.

Clinical Implications for High-Risk Patients

For clinicians managing the complex interplay of autoimmune inflammation and metabolic dysfunction, these findings are highly relevant. Rheumatoid arthritis is often characterized by a chronic proinflammatory state that accelerates atherosclerosis and renal decline. Consequently, the dual-action potential of GLP-1 RAs—targeting both glucose regulation and systemic inflammatory pathways—makes them a promising therapeutic choice for this high-risk population. Moreover, the significant reduction in mortality and kidney events suggests that GLP-1 RAs could be prioritized over DPP-4is in diabetic patients with RA.

Frequently Asked Questions

How do GLP-1 RAs compare to DPP-4 inhibitors in patients with RA and T2D?

In this specific population, GLP-1 RAs were found to be superior to DPP-4is, specifically reducing the risk of death by 32% and kidney-related complications by 11%.

Do GLP-1 RAs reduce cardiovascular events in patients with rheumatoid arthritis?

While the study showed no significant difference in Major Adverse Cardiovascular Events (MACE) compared to DPP-4is, it did show a significant reduction in overall mortality and hospitalizations.

Are GLP-1 RAs beneficial for kidney function in patients with RA?

Yes, research indicates an 11% reduction in Major Adverse Kidney Events (MAKE) for patients with RA and T2D using GLP-1 RAs compared to those using DPP-4is.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a substitute for professional healthcare consultation. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

• Yu YT et al. Association of glucagon-like peptide-1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes. J Diabetes Investig. 2026 Mar 07. doi: 10.1111/jdi.70281. PMID: 41793207.


• Loizidis G, Summer R. GLP-1 Receptor Agonists Reduce Mortality and Cardiovascular Events in Patients with Rheumatoid Arthritis. Arthritis Rheumatol. 2025; 77 (suppl 9).


• Patel S et al. Impact of SGLT2 Inhibitors and GLP-1 Agonists on RA Flares in Patients on DMARD Therapy. ACR Open Rheumatology. 2025.